FCM
Farallon Capital Management Portfolio holdings
AUM
$21.3B
This Quarter Return
+6.19%
1 Year Return
+23.12%
3 Year Return
+87.19%
5 Year Return
+183.94%
10 Year Return
+836.54%
AUM
$9.98B
AUM Growth
+$9.98B
(+4.1%)
Cap. Flow
+$320M
Cap. Flow
% of AUM
3.2%
Top 10 Holdings %
Top 10 Hldgs %
51.68%
Holding
103
New
18
Increased
35
Reduced
17
Closed
19
Top Buys
| 1 |
AET
Aetna Inc
AET
|
$941M |
| 2 |
COL
Rockwell Collins
COL
|
$343M |
| 3 |
MON
Monsanto Co
MON
|
$158M |
| 4 |
Elevance Health
ELV
|
$138M |
| 5 |
Charter Communications
CHTR
|
$91.5M |
Top Sells
| 1 |
BCR
CR Bard Inc.
BCR
|
$508M |
| 2 |
TWX
Time Warner Inc
TWX
|
$380M |
| 3 |
HDS
HD Supply Holdings, Inc.
HDS
|
$196M |
| 4 |
KITE
Kite Pharma, Inc.
KITE
|
$175M |
| 5 |
ALR
Alere Inc
ALR
|
$138M |
Sector Composition
| 1 | Technology | 27.73% |
| 2 | Healthcare | 17.2% |
| 3 | Communication Services | 17.19% |
| 4 | Financials | 14.55% |
| 5 | Industrials | 7.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
NovoCure
NVCR
$1.38B
| $23.5M | 0.19% |
+1,165,000
| New | +$23.5M |
|
52
Intellia Therapeutics
NTLA
$1.33B
| $21.9M | 0.18% |
+1,140,000
| New | +$21.9M |
|
53
CRISPR Therapeutics
CRSP
$4.99B
| $20.2M | 0.16% |
+858,602
| New | +$20.2M |
|
|
HRG
54
DELISTED
HRG Group, Inc.
HRG
| $19.4M | 0.16% |
1,142,000
+157,000
| +16% | +$2.66M |
|
55
Spectrum Brands
SPB
$1.34B
| $19.1M | 0.16% |
170,000
+23,000
| +16% | +$2.59M |
|
56
Protagonist Therapeutics
PTGX
$3.68B
| $18.7M | 0.15% |
+900,000
| New | +$18.7M |
|
57
Editas Medicine
EDIT
$238M
| $15.8M | 0.13% |
+515,000
| New | +$15.8M |
|
|
CAVM
58
DELISTED
Cavium, Inc.
CAVM
| $15.1M | 0.12% |
+180,000
| New | +$15.1M |
|
59
Iovance Biotherapeutics
IOVA
$821M
| $14.9M | 0.12% |
1,866,900
+1,016,900
| +120% | +$8.14M |
|
|
GBT
60
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $13.4M | 0.11% |
+340,000
| New | +$13.4M |
|
61
Hain Celestial
HAIN
$162M
| $12.3M | 0.1% |
+290,000
| New | +$12.3M |
|
62
Akebia Therapeutics
AKBA
$846M
| $12.3M | 0.1% |
825,000
+95,000
| +13% | +$1.41M |
|
63
Assembly Biosciences
ASMB
$184M
| $11.3M | 0.09% |
+250,000
| New | +$11.3M |
|
64
Voyager Therapeutics
VYGR
$215M
| $10.9M | 0.09% |
654,812
+487,147
| +291% | +$8.09M |
|
|
CBAY
65
DELISTED
Cymabay Therapeutics
CBAY
| $10.1M | 0.08% |
+1,100,000
| New | +$10.1M |
|
|
BOLD
66
DELISTED
Audentes Therapeutics, Inc
BOLD
| $9.99M | 0.08% |
+319,662
| New | +$9.99M |
|
|
ZEAL
67
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
| $8.84M | 0.07% |
650,000
| – | – |
|
|
WGL
68
DELISTED
Wgl Holdings
WGL
| $8.58M | 0.07% |
100,000
-20,000
| -17% | -$1.72M |
|
69
XPO
XPO
$14.9B
| $8.24M | 0.07% |
+90,000
| New | +$8.24M |
|
|
MRNS
70
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $7.3M | 0.06% |
895,000
-275,000
| -24% | -$2.24M |
|
71
Bunge Global
BG
$16.2B
| $7.04M | 0.06% |
+105,000
| New | +$7.04M |
|
|
NCNA
72
NuCana
NCNA
$5.92M
| $4.04M | 0.03% |
400,000
| – | – |
|
73
Tronox
TROX
$669M
| $3.88M | 0.03% |
+189,375
| New | +$3.88M |
|
74
KALA BIO
KALA
$91.1M
| $3.42M | 0.03% |
185,000
+85,000
| +85% | +$1.57M |
|
|
SNI
75
DELISTED
Scripps Networks Interactive, Inc Common Class A
SNI
| $3.42M | 0.03% |
40,000
-195,000
| -83% | -$16.6M |
|